Advertisement

Physiology and Pathophysiology of the Parathyroid Glands and Preoperative Evaluation

  • Elizabeth H. Holt
  • Silvio E. Inzucchi
Chapter

19.4 Summary

Calcium homeostasis is of critical importance to living organisms. In man, a complex hormonal system exists to finely regulate the extracellular calcium concentration. A common aberration of this system is primary hyperparathyroidism, the leading cause of chronic hypercalcemia. While usually presenting with few symptoms, this disease is a frequent explanation for osteoporosis and nephrolithiasis. If undiagnosed, it may progress with severe sequelae. It is therefore useful for the surgeon to have a general understanding of the regulation of calcium metabolism as well as the clinical features, diagnostic strategies, and the accepted surgical indications for this common endocrine condition.

Keywords

Serum Calcium Parathyroid Gland Primary Hyperparathyroidism Parathyroid Adenoma Parathyroid Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bringhurst FR (1989) Calcium and phosphate distribution, turnover and metabolic actions. In: DeGroot LJ (ed) Endocrinology, 2nd edn, vol 2. Saunders, Philadelphia, pp 805–843Google Scholar
  2. 2.
    Broadus AE (1999) Mineral balance and homeostasis. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 74–80Google Scholar
  3. 3.
    Brown EM (1999) Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am J Med 106:238PubMedCrossRefGoogle Scholar
  4. 4.
    Norman AW, Roth J, Orci L (1982) The vitamin D endocrine system: steroid metabolism, hormone receptors and biologic response. Endocr Rev 3:331–366PubMedCrossRefGoogle Scholar
  5. 5.
    Dietary Reference Intakes (DRI) and Recommended Dietary Allowances (RDA) (2002) Food and Nutrition Information Center, USDA/ARS/National Agriculture Library, Beltsville, MD. http://www.nal.usda.gov/fnic/etext/000105.htmlGoogle Scholar
  6. 6.
    Wermers RA, Khosla S, Atkinson EJ, Hodgson SF, O’Fallon WM, Melton LJ 3rd (1997) The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965–1992. Ann Intern Med 126:433–440PubMedGoogle Scholar
  7. 7.
    Akerstrom G, Ljunghall S, Lundgren E (1997) Natural history of untreated primary hyperparathyroidism. In: Clark OH, Duh QY (eds) Textbook of endocrine surgery. Saunders, Philadelphia, pp 303–310Google Scholar
  8. 8.
    Silverberg SJ, Bilezikian JP, Bone HG, Talpos GB, Horwitz MJ, Stewart AF (1999) Therapeutic controversies in primary hyperparathyroidism. J Clin Endocrinol Metab 84:2275–2285PubMedCrossRefGoogle Scholar
  9. 9.
    Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671PubMedCrossRefGoogle Scholar
  10. 10.
    Clayman GL, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R (2004) Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 100:900–905PubMedCrossRefGoogle Scholar
  11. 11.
    Chen JD, Morrison C, Zhang C, Kahnoski K, Carpten JD, Teh BT (2003) Hyperparathyroidism-jaw tumour syndrome. J Intern Med 253:634–642PubMedCrossRefGoogle Scholar
  12. 12.
    Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN, Marx SJ (2002) Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine 81:1–26PubMedCrossRefGoogle Scholar
  13. 13.
    Yudd M, Llach F (2000) Current medical management of secondary hyperparathyroidism. Am J Med Sci 320:100–106PubMedCrossRefGoogle Scholar
  14. 14.
    Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, Brandi ML, Drueke TB, Sarfati E, Urena P, Chaganti RS, Arnold A (2002) Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol 13:1490–1498PubMedCrossRefGoogle Scholar
  15. 15.
    Brown EM (2000) Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol Clin North Am 29:503–522CrossRefGoogle Scholar
  16. 16.
    Bendz H, Sjodin I, Toss G, Berglund K (1996) Hyperparathyroidism and long-term lithium therapy: a cross-sectional study and the effect of lithium withdrawal. J Intern Med 240:357–365PubMedCrossRefGoogle Scholar
  17. 17.
    Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373–379PubMedCrossRefGoogle Scholar
  18. 18.
    Strewler GJ (2000) The physiology of parathyroid hormone-related protein. N Engl J Med 342:177–185PubMedCrossRefGoogle Scholar
  19. 19.
    Goltzman D, Karaplis AC, Kremer R, Rabbani SA (2000) Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 88(12 suppl):2903–2908PubMedCrossRefGoogle Scholar
  20. 20.
    Bilezikian JP, Silverberg SJ (2004) Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 350:1746–1751PubMedCrossRefGoogle Scholar
  21. 21.
    Khan A, Bilezikian J (2000) Primary hyperparathyroidism: pathophysiology and impact on bone. Can Med Assoc J 163:184–187Google Scholar
  22. 22.
    Rodman JS, Mahler RJ (2000) Kidney stones as a manifestation of hypercalcemic disorders. Hyperparathyroidism and sarcoidosis. Urol Clin North Am 27:275–285PubMedCrossRefGoogle Scholar
  23. 23.
    Beckerman P, Silver J (1999) Vitamin D and the parathyroid. Am J Med Sci 317:363–369PubMedCrossRefGoogle Scholar
  24. 24.
    Yamashita H, Gao P, Cantor T, Noguchi S, Uchino S, Watanabe S, Ogawa T, Kawamoto H, Fukagawa M (2004) Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. Surgery 135:149–156PubMedCrossRefGoogle Scholar
  25. 25.
    Bilezikian JP, Potts JT Jr, Fuleihan G-H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 87:5353–5361PubMedCrossRefGoogle Scholar
  26. 26.
    Silverberg SJ, Shane E, Jacobs TP, et al (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249PubMedCrossRefGoogle Scholar
  27. 27.
    Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, Skarulis MC, Spiegel AM, Libutti SK, Alexander HR Jr, Chen CC, Chang R, Chandrasekharappa SC, Collins FS (2002) Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 17(suppl 2):N37–N43PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Elizabeth H. Holt
    • 1
  • Silvio E. Inzucchi
    • 1
  1. 1.Section of EndocrinologyYale University School of MedicineNew HavenUSA

Personalised recommendations